1.075
1.42%
+0.015
Adaptimmune Therapeutics Plc ADR stock is currently priced at $1.075, with a 24-hour trading volume of 50,363.
It has seen a +1.42% increased in the last 24 hours and a -29.28% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.07 pivot point. If it approaches the $1.09 resistance level, significant changes may occur.
Previous Close:
$1.06
Open:
$1.06
24h Volume:
50,363
Market Cap:
$270.90M
Revenue:
$60.28M
Net Income/Loss:
$-113.87M
P/E Ratio:
-2.0139
EPS:
-0.5338
Net Cash Flow:
$-145.76M
1W Performance:
+10.06%
1M Performance:
-29.28%
6M Performance:
+91.96%
1Y Performance:
-20.96%
Adaptimmune Therapeutics Plc ADR Stock (ADAP) Company Profile
Name
Adaptimmune Therapeutics Plc ADR
Sector
Industry
Phone
44 12 3543 0000
Address
60 Jubilee Avenue, Milton Park, Abingdon
Adaptimmune Therapeutics Plc ADR Stock (ADAP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-24-23 | Initiated | Bryan Garnier | Buy |
Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
Nov-09-22 | Upgrade | Mizuho | Neutral → Buy |
May-28-21 | Initiated | Barclays | Underweight |
Apr-22-20 | Initiated | Mizuho | Neutral |
Aug-02-19 | Downgrade | Guggenheim | Buy → Neutral |
May-31-19 | Initiated | ROTH Capital | Buy |
May-30-19 | Resumed | Citigroup | Buy |
May-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Mar-17-17 | Initiated | Wells Fargo | Market Perform |
Oct-24-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
Sep-30-16 | Initiated | Raymond James | Outperform |
Feb-25-16 | Initiated | Citigroup | Buy |
Jun-01-15 | Initiated | BofA/Merrill | Neutral |
Jun-01-15 | Initiated | Guggenheim | Buy |
Jun-01-15 | Initiated | Leerink Partners | Outperform |
View All
Adaptimmune Therapeutics Plc ADR Stock (ADAP) Latest News
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Zacks Investment Research
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
Benzinga
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
Zacks Investment Research
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Zacks Investment Research
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Zacks Investment Research
Adaptimmune Therapeutics Plc ADR Stock (ADAP) Financials Data
Adaptimmune Therapeutics Plc ADR (ADAP) Revenue 2024
ADAP reported a revenue (TTM) of $60.28 million for the quarter ending December 31, 2023, a +122.05% rise year-over-year.
Adaptimmune Therapeutics Plc ADR (ADAP) Net Income 2024
ADAP net income (TTM) was -$113.87 million for the quarter ending December 31, 2023, a +31.18% increase year-over-year.
Adaptimmune Therapeutics Plc ADR (ADAP) Cash Flow 2024
ADAP recorded a free cash flow (TTM) of -$145.76 million for the quarter ending December 31, 2023, a +15.01% increase year-over-year.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings per Share 2024
ADAP earnings per share (TTM) was -$0.4738 for the quarter ending December 31, 2023, a +53.55% growth year-over-year.
About Adaptimmune Therapeutics Plc ADR
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Cap:
|
Volume (24h):